Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
The results showed no significant differences in overall survival (OS) or cancer recurrence/metastasis rates between the two treatment methods after a median follow-up of 21 months
A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself
Yes, they are the same compound
Dosing Protocol Suggested nightly titration approach
US$ 23.55
US$ 23.15
US$ 20.71
US$ 24.32
US$ 21.91
US$ 20.49
